​

Monte Rosa Therapeutics Ownership | Who Owns Monte Rosa Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Monte Rosa Therapeutics Ownership Summary

Monte Rosa Therapeutics is owned by 15.16% institutional investors, 0.81% insiders, and 84.03% retail investors. Nea management company is the largest institutional shareholder, holding 9.36% of GLUE shares. Avantis US Small Cap Value ETF is the top mutual fund, with 2.87% of its assets in Monte Rosa Therapeutics shares.

GLUE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMonte Rosa Therapeutics15.16%0.81%84.03%
SectorHealthcare Stocks 232.64%10.66%-143.30%
IndustryBiotech Stocks 382.13%10.41%-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company7.69M9.36%$57.00M
Bvf inc/il5.66M6.89%$41.94M
Baker bros. advisors lp4.92M5.98%$36.43M
Price t rowe associates inc /md/4.64M5.64%$34.36M
Versant venture management4.38M5.32%$68.72M
Blackrock funding, inc. /de4.18M5.07%$65.56M
Suvretta capital management3.36M4.09%$24.90M
Vanguard group3.25M3.94%$50.91M
Blackrock2.36M3.92%$8.83M
Fmr2.81M3.42%$20.84M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Versant venture management4.38M45.49%$68.72M
Aisling capital management lp1.47M4.82%$23.09M
Nea management company7.69M3.13%$57.00M
Silverarc capital management1.03M2.24%$16.14M
Bvf inc/il5.66M1.70%$41.94M
Rangeley capital113.00K0.72%$837.33K
Suvretta capital management3.36M0.64%$24.90M
Parkwood708.00K0.48%$5.25M
Alphabet1.46M0.45%$10.85M
Vestal point capital, lp800.00K0.27%$5.93M

Top Buyers

HolderShares% AssetsChange
Vestal point capital, lp800.00K0.27%800.00K
Fmr2.81M0.00%524.22K
Marshall wace, llp902.83K0.01%456.75K
Norges bank445.87K0.00%445.87K
Blackrock funding, inc. /de4.18M0.00%366.03K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors---3.73M
Price t rowe associates inc /md/4.64M0.00%-1.69M
Versant venture management4.38M45.49%-1.27M
Renaissance---395.73K
Readystate asset management lp---287.00K

New Positions

HolderShares% AssetsChangeValue
Vestal point capital, lp800.00K0.27%800.00K$5.93M
Norges bank445.87K0.00%445.87K$3.09M
Adar1 capital management215.75K0.15%215.75K$1.60M
Rangeley capital113.00K0.72%113.00K$837.33K
Point72 asset management90.42K0.00%90.42K$670.00K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-6.00
Us bancorp \de\-26.00
Capital performance advisors llp-29.00
Skopos labs-92.00
Parkside financial bank & trust-95.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202565-51.13%12,491,437-79.19%150.28%46-24.59%9-77.50%
Sep 30, 202547-59.83%19,971,709-67.89%240.42%21-72.37%16-11.11%
Jun 30, 20251167.41%62,164,3354.44%751.44%7570.45%18-60.87%
Mar 31, 20256-94.44%15,774,831-74.13%190.35%3-95.77%1-94.12%
Dec 31, 202455-34.52%25,603,232-48.56%310.85%40-25.93%4-66.67%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Avantis US Small Cap Value ETF2.30M2.87%-
Vanguard Total Stock Mkt Idx Inv2.16M2.83%-
T. Rowe Price New Horizons2.00M2.63%297.33K
T. Rowe Price Health Sciences1.99M2.61%803.10K
State Street® SPDR® S&P® Biotech ETF1.97M2.46%29.57K
US Small-Cap Growth II Equity Comp1.71M2.24%-1.01K
HBM Healthcare Investments AG Ord1.41M1.85%-
iShares Russell 2000 ETF1.46M1.83%-11.94K
Fidelity Growth Compy Commingled Pl O970.82K1.58%-
T. Rowe Price New Horizons Tr-Z887.19K1.44%1.28K

Recent Insider Transactions

DateNameRoleActivityValue
Apr 14, 2026Warmuth Markus President & CEOSell$141.12K
Apr 09, 2026Nickson Philip Chief Business & Legal OfficerSell$103.41K
Mar 04, 2026Dunn Edmund Principal Accounting OfficerSell$2.50K
Mar 02, 2026Warmuth Markus President & CEOSell$97.97K
Feb 27, 2026Dunn Edmund Principal Accounting OfficerSell$455.51K

Insider Transactions Trends

DateBuySell
2026 Q2-2
2026 Q1-14
2025 Q2-1
2025 Q11-
2024 Q4-3

GLUE Ownership FAQ

Who Owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics shareholders are primarily institutional investors at 15.16%, followed by 0.81% insiders and 84.03% retail investors. The average institutional ownership in Monte Rosa Therapeutics's industry, Biotech Stocks , is 382.13%, which Monte Rosa Therapeutics falls below.

Who owns the most shares of Monte Rosa Therapeutics?

Monte Rosa Therapeutics’s largest shareholders are Nea management company (7.69M shares, 9.36%), Bvf inc/il (5.66M shares, 6.89%), and Baker bros. advisors lp (4.92M shares, 5.98%). Together, they hold 22.23% of Monte Rosa Therapeutics’s total shares outstanding.

Does Blackrock own Monte Rosa Therapeutics?

Yes, BlackRock owns 3.92% of Monte Rosa Therapeutics, totaling 2.36M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 8.83M$. In the last quarter, BlackRock increased its holdings by 53.08K shares, a 2.30% change.

Who is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested, with 45.49% of its assets in 4.38M Monte Rosa Therapeutics shares, valued at 68.72M$.

Who is the top mutual fund holder of Monte Rosa Therapeutics shares?

Avantis US Small Cap Value ETF is the top mutual fund holder of Monte Rosa Therapeutics shares, with 2.87% of its total shares outstanding invested in 2.3M Monte Rosa Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools